<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9683">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00729924</url>
  </required_header>
  <id_info>
    <org_study_id>080536</org_study_id>
    <nct_id>NCT00729924</nct_id>
  </id_info>
  <brief_title>Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid</brief_title>
  <official_title>Genetic Predictors of Raltegravir Penetration Into Cerebrospinal Fluid</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to find out how much of the drug raltegravir (RGV) gets into
      cerebrospinal fluid (CSF), compared to how much get into the blood and to find out if normal
      changes in a certain gene in your body affects how much RGV gets into the CSF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The multidrug efflux transporter P-glycoprotein (P-gp) is expressed in the blood-brain
      barrier where it limits entry of substrate drugs into the central nervous system.
      Raltegravir (MK-0158), a new HIV-1 integrase inhibitor and potentially major addition to the
      therapeutic armamentarium against HIV, is a substrate for P-gp. Studies are warranted to
      elucidate the relevance of P-gp transport for raltegravir in the central nervous system.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">August 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Penetration of Raltegravir (RGV) Into Cerebrospinal Fluid (CSF) Based on Plasma Area-under-the-curve.</measure>
    <time_frame>Day 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome for this study was the ratio of the 4-hour CSF concentration value (ng/mL) to the partial plasma area-under-the-curve 0-4h value (h*ng/mL).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Penetration of Raltegravir (RGV) Into Cerebrospinal Fluid (CSF) Based on Single Plasma Timepoint.</measure>
    <time_frame>Day 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>This outcome was the ratio of the 4-hour CSF concentration value (ng/mL) to the 4-hour plasma concentration value (ng/mL).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Open label oral raltegravir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>400mg orally every 12 hours for 7 days</description>
    <arm_group_label>Open label oral raltegravir</arm_group_label>
    <other_name>MK-0518</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Able to give informed consent.

          2. Negative HIV-1 serology.

          3. At least 18 but no more than 55 years of age.

          4. Body mass index &lt;30.

          5. Estimated creatinine clearance ≥ 50 mL/minute within 30 days prior to study entry.

          6. Within 30 days prior to study entry:

               -  Absolute neutrophil count ≥ 1,000/mm3.

               -  Hemoglobin ≥ 12.5 g/dL for males and ≥ 11.5 g/dL for females.

               -  Platelet count ≥ 100,000/mm3.

               -  AST, ALT, and total bilirubin within normal range.

               -  Alkaline phosphatase &lt; or = 1.5 x upper limit of normal.

          7. Female study volunteers of reproductive potential must have a negative serum or urine
             pregnancy test performed within 30 days before study entry.

          8. Must agree not to participate in a conception process.

          9. Drug transporter gene ABCB1 position 3435 genotype C/C or T/T.

        Exclusion criteria:

          1. Use of any medication that is metabolized by CYP3A or UGT1A1.

          2. Anticipated need to take any medication that is metabolized by CYP3A or UGT1A1 during
             the study.

          3. Active drug use or dependence.

          4. Inability to abstain from alcohol-containing beverages, grapefruit, and grapefruit
             juice.

          5. Serious illness that would interfere with study participation.

          6. Hospitalization for any reason or therapy for serious illness within 14 days prior to
             study entry.

          7. History of hypersensitivity to study drug or its formulation.

          8. As determined by the investigator, a significant active or previous history of
             cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric,
             endocrine, or immunologic disease(s). This is inclusive of chronic illnesses such as
             hypertension, coronary artery disease, arthritis, diabetes, any chronic
             gastrointestinal conditions that may affect drug absorption, etc.

          9. Breast-feeding.

         10. Evidence of CNS infection or space occupying lesion by history or physical
             examination.

         11. History of significant CNS disorder.

         12. Prisoners or subjects who are compulsorily detained.

         13. ABCB1 position 3435 C/T heterozygosity.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David W Haas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt Therapeutics Clinical Research Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Johnson DH, Sutherland D, Acosta EP, Erdem H, Richardson D, Haas DW. Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: a single arm pharmacokinetic study. PLoS One. 2013 Dec 11;8(12):e82672. doi: 10.1371/journal.pone.0082672. eCollection 2013.</citation>
    <PMID>24349334</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 2, 2015</lastchanged_date>
  <firstreceived_date>August 4, 2008</firstreceived_date>
  <firstreceived_results_date>May 27, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>David Haas</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Raltegravir</keyword>
  <keyword>CSF</keyword>
  <keyword>ABCB1 SNP</keyword>
  <keyword>HIV/AIDS</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Raltegravir 400mg Orally Every 12 Hours for 7 Days.</title>
          <description>Raltegravir a single 400mg tablet taken orally every 12 hours for a total of 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Raltegravir: 400mg Orally Every 12 Hours for 7 Days</title>
          <description>Raltegravir a single 400mg tablet taken orally every 12 hours for a total of 7 days.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="34.5" lower_limit="26.8" upper_limit="45"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Cerebrospinal Fluid Protein</title>
          <units>mg/dL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="33" lower_limit="24" upper_limit="43"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="74.6" lower_limit="62.6" upper_limit="80.5"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kilgrams/(meter squared)</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="24.0" lower_limit="22.2" upper_limit="25.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>ABCB1 Genotype</title>
          <description>ABCB1 (rs1045642) C/C or T/T Genotype</description>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>C/C Genotype</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>T/T Genotype</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Penetration of Raltegravir (RGV) Into Cerebrospinal Fluid (CSF) Based on Plasma Area-under-the-curve.</title>
        <description>The primary outcome for this study was the ratio of the 4-hour CSF concentration value (ng/mL) to the partial plasma area-under-the-curve 0-4h value (h*ng/mL).</description>
        <time_frame>Day 7</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir: 400mg Orally Every 12 Hours for 7 Days (ABCB1 C/C</title>
            <description>Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days in participants with ABCB1 C/C genotype.</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir: 400mg Orally Every 12 Hours for 7 Days (ABCB1 T/T</title>
            <description>Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days in participants with ABCB1 T/T genotype.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Penetration of Raltegravir (RGV) Into Cerebrospinal Fluid (CSF) Based on Plasma Area-under-the-curve.</title>
            <description>The primary outcome for this study was the ratio of the 4-hour CSF concentration value (ng/mL) to the partial plasma area-under-the-curve 0-4h value (h*ng/mL).</description>
            <units>1/h</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.0066" lower_limit="0.0050" upper_limit="0.0081"/>
                  <measurement group_id="O2" value="0.0070" lower_limit="0.0060" upper_limit="0.0095"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The hypothesis was that the ratio of the 4-hour CSF concentration value to the partial plasma area-under-the-curve 0-4h value would differ between participants with ABCB1 C/C and T/T genotypes.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.43</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Penetration of Raltegravir (RGV) Into Cerebrospinal Fluid (CSF) Based on Single Plasma Timepoint.</title>
        <description>This outcome was the ratio of the 4-hour CSF concentration value (ng/mL) to the 4-hour plasma concentration value (ng/mL).</description>
        <time_frame>Day 7</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Raltegravir: 400mg Orally Every 12 Hours for 7 Days: ABCB1 C/C</title>
            <description>Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days in participants with ABCB1 C/C genotype.</description>
          </group>
          <group group_id="O2">
            <title>Raltegravir: 400mg Orally Every 12 Hours for 7 Days: ABCB1 T/T</title>
            <description>Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days in participants with ABCB1 T/T genotype.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                  <measurement group_id="O2" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Penetration of Raltegravir (RGV) Into Cerebrospinal Fluid (CSF) Based on Single Plasma Timepoint.</title>
            <description>This outcome was the ratio of the 4-hour CSF concentration value (ng/mL) to the 4-hour plasma concentration value (ng/mL).</description>
            <units>ratio</units>
            <param>Median</param>
            <dispersion>Inter-Quartile Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="0.028" lower_limit="0.014" upper_limit="0.057"/>
                  <measurement group_id="O2" value="0.021" lower_limit="0.016" upper_limit="0.045"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We explored post-hoc whether the ratio of the 4-hour CSF concentration value to the 2-hour plasma concentration differs between participants with ABCB1 C/C and T/T genotypes.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.43</p_value>
            <p_value_desc>The p-value is not adjusted for multiple comparisons.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Raltegravir: 400mg Orally Every 12 Hours for 7 Days</title>
          <description>Raltegravir a single 400 mg pill taken orally every 12 hours for a total of 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>post-lumbar puncture headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no limitations to this trial.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>David W. Haas, MD</name_or_title>
      <organization>Vanderbilt University</organization>
      <phone>615-936-8594</phone>
      <email>david.w.haas@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
